<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788512</url>
  </required_header>
  <id_info>
    <org_study_id>CoCCA</org_study_id>
    <nct_id>NCT03788512</nct_id>
  </id_info>
  <brief_title>Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry</brief_title>
  <acronym>CoCCA</acronym>
  <official_title>Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular
      Disease Patients Registry (CoCCA) is a single-center observational registry of patients
      hospitalized for acute ischemic cerebrovascular disease (AICVD) with atherosclerotic changes
      in both cerebral and coronary arteries.

      This registry aims to establish quantified risk stratification and prognostic models, as well
      as suggest effective diagnostic and therapeutic strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis has exerted huge global burden as the common pathological process underlying
      ischemic heart disease and cerebrovascular disease. A substantial portion of acute ischemic
      cerebrovascular disease (AICVD) patients have both cerebral and coronary atherosclerosis,
      which is an omen of poor outcomes. But there is large evidence gap in these high-risk
      patients' prognosis-related factors, limiting the improvement of care quality.

      Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular
      Disease Patients Registry (CoCCA) is a single-center prospective observational registry of
      patients hospitalized for AICVD with atherosclerotic changes in both cerebral and coronary
      arteries.

      This registry aims to establish quantified risk stratification and prognostic models, as well
      as suggest effective diagnostic and therapeutic strategies.

      The clinical, imaging and laboratory information will be collected at the baseline. During an
      estimated 5-year follow-up, the vessel-related diagnostic or monitoring procedures,
      treatment, functional status and new vascular events will be recorded by web-based patients'
      self-reports, investigators' regular telephone visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2019</start_date>
  <completion_date type="Anticipated">January 12, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Rate of Major Adverse Cardiovascular Events</measure>
    <time_frame>1 year</time_frame>
    <description>cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Major Adverse Cardiovascular Events</measure>
    <time_frame>90 days</time_frame>
    <description>cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Ischemic Stroke</measure>
    <time_frame>1 year</time_frame>
    <description>fatal and nonfatal ischemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Acute Coronary Syndrome</measure>
    <time_frame>1 year</time_frame>
    <description>fatal and nonfatal myocardial infarction and unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Cardiovascular Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Major Adverse Cardiovascular Event</measure>
    <time_frame>5 years</time_frame>
    <description>from the date of enrollment until the date of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina, whichever comes first, assessed up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Ischemic Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>from the date of enrollment until the date of first documented ischemic stroke, assessed up to 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Major Adverse Cardiovascular Events</measure>
    <time_frame>5 years</time_frame>
    <description>cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Ischemic Stroke</measure>
    <time_frame>5 years</time_frame>
    <description>fatal and nonfatal ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Acute Coronary Syndrome</measure>
    <time_frame>5 years</time_frame>
    <description>fatal and nonfatal myocardial infarction and unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Cardiovascular Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coexistence of Cerebral and Coronary Atherosclerosis</condition>
  <condition>Acute Ischemic Cerebrovascular Disease</condition>
  <arm_group>
    <arm_group_label>AICVD patients with CoCCA</arm_group_label>
    <description>acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational only- no intervention</intervention_name>
    <description>observational only- no intervention</description>
    <arm_group_label>AICVD patients with CoCCA</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      anticoagulant peripheral blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary
        atherosclerosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed as ischemic stroke or transient ischemic attack (TIA).

          2. Less than 30 days after onset of ischemic stroke or TIA symptoms.

          3. Extracranial or intracranial cerebral atherosclerosis confirmed by vascular ultrasound
             or CT angiograpgy or MR angiograpgy or digital substraction angiography.

          4. Coronary atherosclerosis confirmed by CT angiograpgy or MR angiograpgy or digital
             substraction angiography; or with myocardial ischemia symptoms confirmed using
             electrocardiogram or echocardiography or cardiac MR; or with a history of percutaneous
             coronary intervention or coronary artery bypass graft.

        Exclusion Criteria:

          1. With malignant tumors or poor organ functions or hematologic diseases, whose estimated
             life expectancy is less than 5 years.

          2. Patients refuse to participate in the research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Ma, MD, PhD</last_name>
    <phone>13501390691</phone>
    <email>maxin118@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Ma, MD, PhD</last_name>
      <phone>13501390691</phone>
      <email>maxin118@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 25, 2018</study_first_submitted>
  <study_first_submitted_qc>December 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2018</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Xin Ma</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>acute ischemic cerebrovascular disease</keyword>
  <keyword>cerebral atherosclerosis</keyword>
  <keyword>coronary atherosclerosis</keyword>
  <keyword>coexistence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

